---
title: "Assembly Biosciences Announces Pricing of $175 Million in Equity Financings | ASMB Stock News"
description: "Assembly Biosciences, Inc. has announced the pricing of a $175 million equity financing, which includes an underwritten offering of 5,591,840 shares of common stock and pre-funded warrants. The offeri"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252230556.md"
published_at: "2025-08-08T12:05:00.000Z"
---

# Assembly Biosciences Announces Pricing of $175 Million in Equity Financings | ASMB Stock News

> Assembly Biosciences, Inc. has announced the pricing of a $175 million equity financing, which includes an underwritten offering of 5,591,840 shares of common stock and pre-funded warrants. The offering price is set at $19.60 per share, with participation from various investors, including Gilead Sciences, which will purchase 2,295,920 shares in a private placement. The proceeds will be used for general corporate purposes, and the transactions are expected to close on August 11, 2025, subject to customary conditions.

08/08/2025 - 08:05 AM

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (“Assembly Bio”) (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced the pricing of an underwritten, registered offering (the “offering”) of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded warrant and accompanying Class A warrant and Class B warrant of $19.599. Each pre-funded warrant will have a nominal exercise price of $0.001 per share of common stock and will be immediately exercisable. Each accompanying Class A warrant will have an exercise price of $21.60 per share of common stock, will be immediately exercisable and will expire on the earlier of (i) five years from the date of issuance (August 11, 2030) and (ii) the date that is 30 days after the public announcement that Assembly Bio has completed enrollment (of at least 200 patients total) for its Phase 2 clinical study evaluating ABI-5366 vs. valacyclovir. Each accompanying Class B warrant will have an exercise price of $21.60 per share of common stock, will be exercisable on or after November 15, 2026 and will expire on December 31, 2026, provided that each Class B warrant will automatically terminate in full and be extinguished and shall no longer be exercisable in the event that Assembly Bio publicly announces prior to November 15, 2026 that it has received at least $75.0 million in the aggregate of non-dilutive capital in connection with a collaboration agreement.

The offering includes participation from new and existing investors, including Commodore Capital, Blackstone Multi-Asset Investing, Farallon Capital Management, L.L.C., Janus Henderson Investors, RA Capital Management, a large investment management firm, and other healthcare dedicated funds.

In addition to the offering, Assembly Bio announced that Gilead Sciences, Inc. (“Gilead”) will purchase 2,295,920 shares of common stock and accompanying Class A warrants and Class B warrants to purchase up to an aggregate of 2,295,920 shares of common stock in a private placement (the “private placement”) at a price per share, together with accompanying warrants, equal to the offering price described above. The sale of the securities in the private placement will not be registered under the Securities Act of 1933, as amended (the “Securities Act”).

The offering and the private placement are expected to close on August 11, 2025, subject to the satisfaction of customary closing conditions. The closing of the offering and the closing of the private placement are contingent upon one another.

Assembly Bio plans to use the net proceeds from the offering and the private placement for general corporate purposes.

Guggenheim Securities is acting as lead book-running manager for the offering. Mizuho is also acting as a book-running manager for the offering.

Registration statements relating to the securities being sold in the offering have been filed with the Securities and Exchange Commission (“SEC”) and are effective. A preliminary prospectus supplement and a final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the preliminary prospectus supplement and final prospectus supplement may be obtained by contacting Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, New York 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or Mizuho, c/o Mizuho Securities USA LLC, 1271 Avenue of the Americas, New York, New York 10020 or by email at US-ECM@mizuhogroup.com, Attention: Equity Capital Markets.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

**About Assembly Biosciences**

Assembly Biosciences is a biotechnology company dedicated to the development of innovative small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections.

**Forward-Looking Statements**

The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These forward-looking statements include statements about the proposed offering and the proposed private placement, including the expected timing and completion thereof and the use of proceeds therefrom. These risks and uncertainties include: Assembly Bio’s ability to maintain financial resources and secure additional funding necessary to continue its research activities, clinical studies, other business operations and continue as a going concern; Assembly Bio’s ability to realize the potential benefits of its collaboration with Gilead, including all financial aspects of the collaboration and equity investments; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration with Gilead, in the currently anticipated timeframes or at all; safety and efficacy data from clinical or nonclinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data may not differentiate Assembly Bio’s product candidates from other companies’ candidates; potential effects of changes in government regulation, including as a result of the change in U.S. administration in 2025; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the SEC. You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

**Contacts**  
**Investor and Corporate:**  
Shannon Ryan  
SVP, Investor Relations, Corporate Affairs and Alliance Management  
(415) 738-2992  
investor\_relations@assemblybio.com

### Related Stocks

- [ASMB.US - Assembly Biosciences](https://longbridge.com/en/quote/ASMB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| ACROBiosystems 在 bioSeedin 的 JPM Spotlight 會議上推動創新，並戰略性地支持全球合作伙伴關係的建立 | ACROBiosystems 參加了於 1 月 11 日舉行的 BIOSeedin 冬季創新合作峯會，此次峯會在舊金山的 J.P. Morgan 2026 之前舉行。此次活動以 “創新資產的全球匹配” 為主題，匯聚了跨國製藥公司、投資者和生 | [Link](https://longbridge.com/en/news/275692064.md) |
| NFL 生物科技大幅提高了其戒煙療效目標 | NFL 生物科學公司已提高其戒煙藥物候選者 NFL-101 和 NFL-102 的療效目標，基於新數據揭示了一種新的作用機制。NFL-101 專注於神經炎症，而 NFL-102 則旨在提高在吸煙人羣中的廣泛療效。該公司正在積極尋求戰略合作伙 | [Link](https://longbridge.com/en/news/273729830.md) |
| 閃迪會成為下一個英偉達嗎？ | 閃迪從西部數據分拆出來以來，其股票自納斯達克迴歸以來已上漲超過 1500%。隨着對人工智能基礎設施需求的增長，閃迪專注於 DRAM 和 NAND 解決方案，使其在市場中處於有利位置。分析師預測強勁的盈利增長，前瞻市盈率為 15，表明其相較於 | [Link](https://longbridge.com/en/news/276063622.md) |
| 期權熱點｜上周五 NBIS 大漲 9%，部分看漲期權飆升 378% | 美東時間 2026-02-13，Nebius 期權總成交 179098 張，看漲期權佔比 71%，看跌期權佔比 28%。 | [Link](https://longbridge.com/en/news/276030151.md) |
| 對派拓網絡收益的預期 | 派拓網絡（NASDAQ:PANW）定於 2026 年 2 月 17 日發佈季度財報，分析師預計每股收益（EPS）為 0.76 美元。投資者對積極的指引抱有希望，尤其是在公司之前超出 EPS 預期後，股價卻隨之下跌了 7.42%。目前，股價為 | [Link](https://longbridge.com/en/news/276061399.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.